JP2019150066A5 - - Google Patents

Download PDF

Info

Publication number
JP2019150066A5
JP2019150066A5 JP2019113625A JP2019113625A JP2019150066A5 JP 2019150066 A5 JP2019150066 A5 JP 2019150066A5 JP 2019113625 A JP2019113625 A JP 2019113625A JP 2019113625 A JP2019113625 A JP 2019113625A JP 2019150066 A5 JP2019150066 A5 JP 2019150066A5
Authority
JP
Japan
Prior art keywords
nucleic acid
polypeptide
acid sequence
domain
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019113625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019150066A (ja
JP6979423B2 (ja
Filing date
Publication date
Priority claimed from GBGB1514875.2A external-priority patent/GB201514875D0/en
Application filed filed Critical
Publication of JP2019150066A publication Critical patent/JP2019150066A/ja
Priority to JP2020199336A priority Critical patent/JP7603426B2/ja
Publication of JP2019150066A5 publication Critical patent/JP2019150066A5/ja
Application granted granted Critical
Publication of JP6979423B2 publication Critical patent/JP6979423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019113625A 2015-08-20 2019-06-19 キメラサイトカイン受容体 Active JP6979423B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020199336A JP7603426B2 (ja) 2015-08-20 2020-12-01 キメラサイトカイン受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1514875.2A GB201514875D0 (en) 2015-08-20 2015-08-20 Receptor
GB1514875.2 2015-08-20
JP2018509549A JP2018523485A (ja) 2015-08-20 2016-08-19 キメラサイトカイン受容体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018509549A Division JP2018523485A (ja) 2015-08-20 2016-08-19 キメラサイトカイン受容体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020199336A Division JP7603426B2 (ja) 2015-08-20 2020-12-01 キメラサイトカイン受容体

Publications (3)

Publication Number Publication Date
JP2019150066A JP2019150066A (ja) 2019-09-12
JP2019150066A5 true JP2019150066A5 (enExample) 2021-01-21
JP6979423B2 JP6979423B2 (ja) 2021-12-15

Family

ID=54292003

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2018509549A Withdrawn JP2018523485A (ja) 2015-08-20 2016-08-19 キメラサイトカイン受容体
JP2019113625A Active JP6979423B2 (ja) 2015-08-20 2019-06-19 キメラサイトカイン受容体
JP2020199336A Active JP7603426B2 (ja) 2015-08-20 2020-12-01 キメラサイトカイン受容体
JP2022178045A Withdrawn JP2022190153A (ja) 2015-08-20 2022-11-07 キメラサイトカイン受容体
JP2025047075A Pending JP2025089404A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体
JP2025047074A Pending JP2025089403A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018509549A Withdrawn JP2018523485A (ja) 2015-08-20 2016-08-19 キメラサイトカイン受容体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020199336A Active JP7603426B2 (ja) 2015-08-20 2020-12-01 キメラサイトカイン受容体
JP2022178045A Withdrawn JP2022190153A (ja) 2015-08-20 2022-11-07 キメラサイトカイン受容体
JP2025047075A Pending JP2025089404A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体
JP2025047074A Pending JP2025089403A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体

Country Status (17)

Country Link
US (6) US10800854B2 (enExample)
EP (3) EP3438123A1 (enExample)
JP (6) JP2018523485A (enExample)
KR (2) KR102669749B1 (enExample)
CN (2) CN110724200B (enExample)
AU (1) AU2016308618B2 (enExample)
BR (1) BR112018003308A2 (enExample)
CA (2) CA2995785A1 (enExample)
CL (2) CL2018000415A1 (enExample)
GB (1) GB201514875D0 (enExample)
HK (1) HK1252161A1 (enExample)
IL (2) IL270207B2 (enExample)
MX (2) MX2018002042A (enExample)
RU (1) RU2018109350A (enExample)
SG (1) SG10201909759UA (enExample)
WO (1) WO2017029512A1 (enExample)
ZA (1) ZA201904156B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
IL309526B2 (en) 2016-11-17 2025-02-01 2Seventy Bio Inc TGFBeta signal converter
AU2017378153B2 (en) * 2016-12-13 2024-03-28 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3679145A2 (en) * 2017-09-08 2020-07-15 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
GB201714718D0 (en) 2017-09-13 2017-10-25 Autolus Ltd Cell
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
GB201719557D0 (en) * 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
EP3723787A4 (en) * 2017-12-14 2021-09-01 Bluebird Bio, Inc. DARIC INTERLEUKIN RECEPTORS
AU2019209428B2 (en) 2018-01-22 2025-06-26 Endocyte, Inc. Methods of use for CAR T cells
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
EP3759132A1 (en) * 2018-03-02 2021-01-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2019200056A2 (en) 2018-04-12 2019-10-17 Vivo-Til Therapeutics Inc. Viral vectors and packaging cell lines
CN112041436A (zh) 2018-04-27 2020-12-04 西雅图儿童医院(Dba西雅图儿童研究所) 雷帕霉素抗性细胞
EP3806904A4 (en) * 2018-06-18 2022-04-27 Eureka Therapeutics, Inc. PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED CONSTRUCTS AND USES THEREOF
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
US12486514B2 (en) * 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
PL3856775T3 (pl) 2018-09-27 2025-06-09 Autolus Limited Chimeryczny receptor antygenowy
US20200147137A1 (en) * 2018-11-08 2020-05-14 WUGEN, Inc. Compositions and methods for treatment of cancer
CN111378046B (zh) * 2018-12-27 2024-03-15 上海细胞治疗集团有限公司 一种免疫效应细胞转换受体
CA3129862A1 (en) * 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a pd-1 ectodomain
CN113508128B (zh) 2019-03-01 2025-11-04 艾洛基治疗公司 组成型活性嵌合细胞因子受体
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
US20220145325A1 (en) * 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
GB201911187D0 (en) 2019-08-05 2019-09-18 Autolus Ltd Receptor
EP4021582A1 (en) 2019-08-30 2022-07-06 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising tgf beta binding domains
AU2020346824A1 (en) * 2019-09-11 2022-03-31 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
KR102275668B1 (ko) * 2019-09-26 2021-07-12 충북대학교 산학협력단 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
JP2022551909A (ja) * 2019-10-10 2022-12-14 ブライオロジクス インコーポレイテッド ブリオスタチンによる腫瘍関連抗原の誘導方法
EP4100428A4 (en) 2020-02-04 2024-03-06 Seattle Children's Hospital (DBA Seattle Children's Research Institute) CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
TWI894211B (zh) 2020-02-24 2025-08-21 美商異基因治療有限公司 具有增強活性之bcma car-t細胞
TW202146431A (zh) 2020-02-25 2021-12-16 英商圭爾醫療有限公司 用於經工程化細胞之嵌合受體
CA3172691A1 (en) 2020-03-31 2021-10-07 Cameron J. Turtle Chimeric antigen receptors targeting cd33
EP4126925A4 (en) * 2020-03-31 2024-07-24 Fred Hutchinson Cancer Center CHIMERIC ANTIGEN RECEPTORS TARGETED AGAINST CD33
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
WO2021205175A1 (en) 2020-04-09 2021-10-14 Autolus Limited Molecule
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
CN113201063B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途
WO2022037562A1 (en) * 2020-08-17 2022-02-24 Nanjing Legend Biotech Co., Ltd. Engineered immunoresponsive cells and uses thereof
CN112961248B (zh) * 2021-02-22 2022-03-18 广州百暨基因科技有限公司 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用
CN113072648B (zh) * 2021-06-04 2021-08-24 诺未科技(北京)有限公司 一种靶向afp的肝癌疫苗
CN113416708A (zh) * 2021-06-10 2021-09-21 深圳市先康达生命科学有限公司 一种表达细胞因子受体融合型嵌合抗原受体的免疫细胞及其应用
KR102827437B1 (ko) * 2021-08-30 2025-07-02 연세대학교 산학협력단 림프종의 예방 또는 치료를 위한 림프종 세포 특이적 약물 전달체 및 이의 제조방법
AU2022347445A1 (en) * 2021-09-17 2024-04-04 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
EP4519294A1 (en) * 2022-05-04 2025-03-12 Earli Inc. Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells
CN119768508A (zh) * 2022-07-11 2025-04-04 索诺玛生物治疗公司 重组细胞因子受体及其使用方法
WO2024044768A2 (en) * 2022-08-26 2024-02-29 The Board Of Trustees Of The Leland Stanford Junior University Chimeric cytokine receptors and methods of use
CN117402262A (zh) * 2022-10-19 2024-01-16 上海君赛生物科技有限公司 基于lag3的嵌合免疫细胞辅助受体及其用途
EP4630446A1 (en) * 2022-12-06 2025-10-15 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
IL322256A (en) 2023-01-23 2025-09-01 Medizinische Hochschule Hannover Anti-ENTPD3 chimeric antigen receptor
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
IL322333A (en) 2023-02-07 2025-09-01 Quell Therapeutics Ltd Culture method for TREG cells
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Psma及びca9を標的とするシステム
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
CN120917054A (zh) 2023-03-20 2025-11-07 奥托路斯有限公司 嵌合细胞因子受体,其包含截短的IL2Rβ和IL2Rγ
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
CN121586582A (zh) 2023-03-20 2026-02-27 汉诺威医学院 嵌合抗原受体
WO2024238287A1 (en) * 2023-05-12 2024-11-21 Chimeris Uk Ltd. Dual blocking and chimeric cytokine receptor
GB202309704D0 (en) 2023-06-27 2023-08-09 Autolus Ltd Chimeric transmembrane protein
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
WO2025189046A2 (en) * 2024-03-06 2025-09-12 The Johns Hopkins University Pantigen specific cytokine receptor stimulation of immune cell function
WO2025221843A1 (en) * 2024-04-17 2025-10-23 Baylor College Of Medicine Methods and compositions for suppressing immune cell activation
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683073B2 (en) 1993-06-07 1997-10-30 Amgen, Inc. Hybrid receptor molecules
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
AU758949B2 (en) * 1998-05-19 2003-04-03 Avidex Limited Multivalent T cell receptor complexes
ATE432942T1 (de) * 2001-03-09 2009-06-15 Zymogenetics Inc Löslicher heterodimerer cytokinrezeptor
CN1659274A (zh) * 2002-04-19 2005-08-24 津莫吉尼蒂克斯公司 细胞因子受体
JP2004113062A (ja) 2002-09-25 2004-04-15 Teruyuki Nagamune キメラ受容体を有する動物細胞とその利用
CN101027079B (zh) * 2004-10-12 2011-08-17 美国蛋白质公司 嵌合蛋白
WO2007115230A2 (en) 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US20110038865A1 (en) * 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
WO2010085660A2 (en) 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
NZ616405A (en) 2011-04-08 2015-11-27 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
RU2522004C2 (ru) 2012-04-10 2014-07-10 Владимир Константинович Боженко Одноцепочечное антитело к раково-эмбриональному антигену, химерный мономолекулярный т-клеточный рецептор, вектор и клетка-хозяин для обеспечения экспрессии такого рецептора и способ диагностики или лечения.
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
MA41538A (fr) * 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518817D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Cell
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201719557D0 (en) 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
PL3856775T3 (pl) 2018-09-27 2025-06-09 Autolus Limited Chimeryczny receptor antygenowy

Similar Documents

Publication Publication Date Title
JP2019150066A5 (enExample)
JP2021035395A5 (enExample)
CN110662560B (zh) 改进的抗原结合受体
JP2023091037A (ja) Gタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用
CN109069537B (zh) 共刺激结构域中具有重复结合基序的car
JP2019535262A5 (enExample)
JP2022109953A5 (enExample)
CN108350462B (zh) 嵌合抗原受体及其用途
JP2018523485A5 (enExample)
JP2018532407A5 (enExample)
CN109789164B (zh) 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体
JP2018523484A5 (enExample)
Murad et al. Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
JP2018526033A5 (enExample)
TW201841944A (zh) 4-1bbl變異體及包含其之融合蛋白
CN114391021A (zh) TGF-β受体和使用方法
CN111479918A (zh) 细胞
CN114957481A (zh) 针对cd19和cd22的双靶点star
CN116096739A (zh) 嵌合抗原受体间隔物
JP2023527613A (ja) G12v変異を有するrasに対するhlaクラスii拘束性t細胞受容体
CN112996819B (zh) 细胞分选系统及使用方法
CN114286691B (zh) Cs1-抗体和抗cs1-car-t细胞
EP4387656A1 (en) Binding domain
CN115521917A (zh) 工程化免疫细胞及其用途
JP4635255B2 (ja) 抗体医薬